Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 26, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 12,376 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on June 22, 2006, and the Company was advised of it on June 23, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the impact of the 12,376 share transfer on the total outstanding share count.
- Confirm the specific identities of the participants in the SmithKline Beecham Employee Share Option Plan 1991 who received the shares.
- Note that Directors Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop hold interests in the GSK Trust as potential beneficiaries alongside other employees.